Code Biotherapeutics Raises Upsized and Oversubscribed $75 Million in Series A Financing to Develop Therapies for Debilitating Genetic Diseases

– Round led by Northpond Ventures with participation from new investors Amgen Ventures, Hatteras Venture Partners and UCB Ventures alongside existing investors – Proceeds will enable Code Bio to advance its lead programs in Duchenne Muscular Dystrophy (DMD) and type 1 diabetes (T1D) towards IND-enabling studies, expand its pipeline and platform applications, and further scale … [Read more…]

Thomas H. Lee Partners Appoints Sam Hendler As Head of Business Development, Healthcare

Industry Veteran Will Lead Sourcing Strategy for the Firm’s Healthcare Group BOSTON–(BUSINESS WIRE)–Thomas H. Lee Partners, L.P. (“THL”), a premier private equity firm investing in middle-market growth companies, today announced the appointment of Sam Hendler as Managing Director and Head of Business Development for the firm’s healthcare investment group. Hendler, who brings over 20 years … [Read more…]

Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

Interim results show improved symptoms of psychosis in patients with chronic TRS Study 014 represents first international trial of a New Chemical Entity (NCE) antipsychotic as an add-on in TRS, with treatment implications for TRS patients Newron to host an investor, analyst and media conference call today at 3 pm CET/ 9 am ET Ad … [Read more…]

Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl

Innovating Every Day.TM BRIDGEWATER, N.J.–(BUSINESS WIRE)–#chewable–Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037. “Cosette … [Read more…]

STAAR Surgical Celebrates Two Million Lens Milestone for Implantable Collamer® Lens (ICL)

Milestone Follows U.S. FDA Approval of EVO Visian® ICL in March EVO Offers Visual Freedom from Glasses and Contact Lenses LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian® Implantable Collamer lenses … [Read more…]

Study Shows Significantly Reduced Airborne Bacteria in Urgent Care Outpatient Facility Using WellAir’s Defend 400

Rooms using the device showed a 52% reduced total bacterial count over a 5-day period, including a 60% reduction in opportunistic pathogens STAMFORD, Conn.–(BUSINESS WIRE)–WellAir, a leading provider of indoor air disinfection and purification solutions, today released real-world test results demonstrating how its Defend 400 device reduced airborne bacteria at an urgent care outpatient facility … [Read more…]

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

– ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study – 91.3% sustained clinical response achieved at eight weeks in overall population with consistent results in key subpopulations including first recurrence – – Rolling Biologics License Application (BLA) submission initiated and on track for … [Read more…]

Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference

New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease Significant Effects of ALZ-801 on Beta Amyloid and Tau Biomarkers in Patients with Alzheimer’s Support its Clinical Development in Genetically Determined Disorders of Brain … [Read more…]

Biodesix Obtains Medicare Coverage for the Nodify CDT® Lung Nodule Test

BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced that WPS Government Health Administrators, the Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, has provided coverage for the Nodify CDT® lung nodule test. The Nodify CDT test is a part of the … [Read more…]

RARE-X Releases New Report that Uncovers Large Number of Previously Uncounted Rare Diseases

–             The “Power of Being Counted” Report reveals previously severely undercounted numbers used for decades to define rare diseases and help shape policies and biomedical discovery –       Study provides critical data to global researchers, clinicians, drug developers and patient advocates in their mission to improve outcomes for patients WASHINGTON–(BUSINESS WIRE)–RARE-X, a nonprofit organization dedicated to … [Read more…]